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Abstract
High adherence is key to microbicide effectiveness. Here we provide a description of adherence
interventions and the adherence rates achieved in the CAPRISA 004 Tenofovir Gel Trial.
Adherence support for the before-and-after dosing strategy (BAT 24) was provided at enrolment
and at each monthly study visit. This initially comprised individual counselling and was replaced
midway by a structured theory-based adherence support program (ASP) based on motivational
interviewing. The 889 women were followed for an average of 18 months and attended a total of
17031 monthly visits. On average women reported 5 sex acts and returned 5.9 empty applicators
per month. The adherence rate based on applicator count in relation to all reported sex acts was
72.2% compared to the 82.0% self-reported adherence during the last sex act. Adherence support
activities, which achieve levels of adherence similar to or better than those achieved by the
CAPRISA 004 ASP, will be critical to the success of future microbicide trials.
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INTRODUCTION
Young women bear a disproportionate burden of HIV infection in sub-Saharan Africa with
HIV infection rates about 3-6 fold higher than that observed in young men (1). Microbicides
offer a promising female-controlled option for HIV prevention. While findings from phase
III trials of Nonoxynol-9 (2), SAVVY (3, 4), Carraguard (5) and Cellulose Sulphate (6, 7)
have been disappointing, tenofovir gel offers a promising female-controlled option as an
effective microbicide for HIV prevention (8).
The effectiveness of a microbicide in a clinical trial is dependent on the efficacy of the
product as well as the participants’ willingness and ability to use the product as instructed
(9). For example, the effectiveness of a 100% efficacious product, which is used only 50%
of the time, can be expected to be only 50%. This will depend on, amongst other issues, the
risk profile of the participant, study product dosing strategy and timing of product use.
Corresponding author: Leila E Mansoor Centre for the AIDS Program of Research in South Africa 2nd Floor, Doris Duke Medical
Research Institute Nelson R Mandela School of Medicine University of KwaZulu-Natal Private Bag X7 Congella, 4013 South Africa
Tel: +2731 260 4641 Fax: +2731 260 4549 mansoor@ukzn.ac.za.
NIH Public Access
Author Manuscript
AIDS Behav. Author manuscript; available in PMC 2015 May 01.
Published in final edited form as:






















Under-utilization or inappropriate use of product, especially in relation to exposure to HIV,
is a serious threat to a microbicide trial being able to demonstrate an accurate level of
product efficacy. Indeed, low adherence has been identified as being responsible for the lack
of effectiveness in the FEM-PrEP trial, a study of daily oral antiretroviral prophylaxis in
women (10) and in the MTN 003 (VOICE) trial, a study of daily oral and vaginal
antiretroviral prophylaxis in women (11).
Adherence is multidimensional, involving the interplay of, amongst others, participant
behavior, adverse effect profiles, patient fatigue, and integration of therapy into the routine
of daily living (12). In a clinical trial it is particularly challenging to achieve high adherence,
due to participants being repeatedly informed that they may be allocated to placebo or active
arms, and that the true efficacy of the study product is as yet unknown.
There is, at present, no reference standard for measuring adherence in microbicide trials. In
2008, the Institute of Medicine (13) recommended that ‘investigators should use multiple
types of measures to triangulate adherence estimates’. The report further recommended that
interventions to increase adherence should be ‘methodologically rigorous, socially and
culturally relevant, [and] grounded in behavioral and social science theories’.
The CAPRISA 004 trial assessed the safety and effectiveness of tenofovir gel in preventing
sexually transmitted HIV infection in women. Here we describe the study product adherence
achieved, using three different measures of gel adherence, through adherence activities
implemented in the CAPRISA 004 Tenofovir Gel Microbicide trial. Additionally, we
describe the relationship between gel adherence and HIV effectiveness.
METHODS
Study design and study population
CAPRISA 004 was a phase IIb, two-arm, double-blind, randomized, controlled trial to
assess the effectiveness of tenofovir gel. The trial was conducted from May 2007 to March
2010. A total of 889 HIV-uninfected women between 18 and 40 years were eligibly enrolled
at two sites: the CAPRISA Vulindlela Clinic in a rural community about 150 km west of
Durban in the KwaZulu-Natal midlands (rural site); and CAPRISA eThekwini Clinic in
central Durban (urban site). Participants were followed for a mean of 18 months (8).
Tenofovir gel dosing regimen
The dosing and timing of tenofovir gel in the CAPRISA 004 trial was informed by a review
of non-human primate studies (14), safety studies of topical tenofovir (15), and extensive
consultation with potential study participants (16). The dosing strategy comprised three key
concepts described as “BAT24”:
• Insert first gel up to 12 hours Before sex
• Insert second gel as soon as possible, within 12 hours After sex
• Do not insert more than Two gels in a 24 hour period
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Interventions to support gel use
The design of the CAPRISA 004 trial drew upon the experiences and benefited from
previous microbicide trials, particularly in relation to the importance of adherence support.
During the CAPRISA 004 trial preparation phase, several structured meetings and
discussions were held with the target population and selected study staff (including
clinicians, nurses, counselors, and research assistants) to develop and modify the design of
the adherence activities. Adherence activities were adapted to accommodate participants’
literacy levels, cultural beliefs, attitudes and expectations. Support materials used to
facilitate adherence activities are shown and described in Table 1.
During the trial the adherence activities were regularly reviewed and adapted as needed. The
adherence activities initially comprised individual counselling and this was adapted midway
(from October 2008 onwards), based on an Information-Motivation-Behavioral (IMB) skills
model framework (17). Depending on when a woman was enrolled into the trial, the
duration of exposure to the adapted adherence activities differ. This model encompasses
provision of information, motivation and self-efficacy to support desired behavior change,
and skills needed for the desired behavior (17). The IMB model has been studied in various
populations in both prevention and treatment settings (18-23) and has been proposed to
sustain adherence in microbicide trials (24). Table 2 summarizes the IMB model for the
Adherence Support Program (ASP) in the CAPRISA 004 trial.
The IMB adaptation included the introduction of a motivational interviewing approach
(25-27) to facilitate a participant-centered, collaborative discussion to explore and resolve
any obstacles or ambivalence to adherence. During the motivational interviewing based
sessions, a trained nurse encouraged each woman to discuss how she thought she could
incorporate gel use into her routine activities. The impact of motivational interviewing based
counseling on adherence and gel effectiveness have been previously described in detail (28).
Adherence support was provided at screening, enrollment, and monthly follow-up visits
according to the following structure:
1. Screening module - As part of the decision-making for trial participation, women
were given basic information on the use of study gel, followed by an introduction
to the applicator and study gel.
2. Enrollment module - Once enrolled, women were provided with detailed
instructions on how to use study gel while in the trial. The main goals of this
module were to familiarize women with the mechanics of using the applicator, to
communicate the timing and dosing message for gel use, and to freely engage
nurses with questions that they may have with gel use in relation to sexual
experience.
3. Booster module - During monthly follow-up visits, women were provided with
ongoing counseling to support gel use. These included customized support based
on previous month's experience of gel use as well as goal setting.
The modules were administered through individualized sessions by trained nurses. Initially,
measurement of gel use occurred by the same nurses who were also responsible for
Mansoor Page 3






















adherence support. When the motivational interviewing approach was introduced,
behavioral data were collected independently from the provision of adherence support.
ASP materials were modified during the trial based on the opinions of the staff
administering the ASP and the women in the study. These opinions were systematically
collected and collated through qualitative, structured debriefing and interactive sessions with
the nurses administering the ASP. In total, 26 debriefing sessions, each lasting
approximately two hours, were hosted by the ASP Coordinator during the trial to review
strengths and weaknesses of the content, structure and delivery of the ASP. These sessions
focused on staff opinions of the program, on their interactions with the women, as well as
the opinions of the participants. Specifically, the knowledge, behavior and motivation for
adherence to gel use was monitored and discussed. The ASP Coordinator provided ongoing
advice and support to the staff based on feedback received during the debriefing sessions
(Figure 1).
Adherence measurements
At each monthly follow-up visit, self-reported behavioral data on sexual frequency and gel
use were collected using interviewer administered standardized questionnaires for the
preceding 30 days, last 7 days and day of last sex act. Timing of self-reported gel and
condom use relative to sex were collected for the last sex act only. From October 2007,
about 4 months after study initiation, the participants were requested to return all their used
and unused gel applicators from the preceding month at each follow-up visit. These were
counted and reconciled against the number of applicators dispensed previously.
Three different measures of gel adherence are defined below:
1. Returned used applicator adherence: The number of returned used applicators was
recorded at each monthly visit for each woman; an adherence score was calculated
as the median number of applicators returned per study visit (excluding missed
study visits). Applicators that were not returned to the pharmacy were regarded as
not used for the purposes of the adherence analysis. Women returning more than a
median of 9 applicators per month over the trial period were classified as high gel
users, those returning a median of 5 to 9 applicators on average per month were
regarded as intermediate gel users and those returning less than a median of 5
applicators per month were considered to be low gel users.
2. Self-reported adherence: Women were asked detailed questions about the last day
they had sex, including whether the study gel was used up to 12 hours before and
after the last sex act. If gel was used according to the prescribed dosing regimen,
the woman was regarded as being adherent that month. If no study gel or only one
study gel was used within the appropriate time period, or if a study visit was missed
or data on the last sex act was not collected, the woman was classified as non-
adherent for that month. An adherence score was calculated for each woman,
representing the proportion of adherent sex acts over all sex acts. Women with an
adherence score of 100% were considered to be high adherers, whilst those with a
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score of 80% to 99% were intermediate adherers and those with a score of less than
80% were low adherers.
3. Applicator-based adherence: This measure was regarded as the primary adherence
measure and has been reported previously (8). It was calculated by dividing the
number of reported sex acts per month by half the number of returned used
applicators for that month. The median of each woman's monthly adherence
estimates was assigned as her overall gel adherence score. The assumption was that
two doses of gel were required for every reported sex act. Although this assumption
may not always apply, adjusting for multiple sex acts within 24 hours made no
substantive difference. Women who used two doses of gel in more than 80% of
their last sex acts were regarded as high adherers, those using two doses of gel in
50 to 79% of their last sex acts were regarded intermediate adherers and those
using two doses of gel in less than 50% of their last sex act were regarded as low
adherers.
Statistical analysis
We analyzed the final dataset (datalock date 09 December 2011). The differences between
the final dataset and the previously published data (8) are minor and do not impact the
overall results. HIV incidence rates and incidence rate ratios (IRRs) between tenofovir gel
and placebo gel were calculated for each adherence measurement, stratified and reported as
low, intermediate, or high to assess the relationship between each adherence measurement
and effectiveness of tenofovir gel for HIV prevention.
A Poisson distribution was assumed for confidence intervals (CIs) of incidence rate ratios
(IRRs). Stratified analyses of gel effectiveness in each of the adherence levels (high,
intermediate, low) was evaluated using a log-rank test, adjusted for site. Categories were
defined post hoc and were not based on a specific theoretical framework. All p-values are
two-sided and CIs are 95%. The descriptive and statistical analysis of data was performed
using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
The CAPRISA 004 trial (NCT00441298) was approved by the University of KwaZulu-
Natal's Biomedical Research Ethics Committee (E111/06), FHI's Protection of Human
Subjects Committee (#9946) and the South African Medicine Control Council (#20060835).
RESULTS
Demographics
A total of 278 urban and 611 rural women were eligibly enrolled and followed-up for a total
of 1341 women-years (mean=18 months), attended 17031 monthly visits with an overall
study retention rate of 94.8% (8). There were no significant differences in the demographic
characteristics and baseline sexual behavior of participants in the tenofovir gel arm (n=445)
compared to the placebo gel arm (n=444) (8).
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Returned used applicator adherence
During the trial, a total of 181,870 applicators were dispensed, of which 95.3% were
returned to the study pharmacy. Of these, 93,597 (51.5%) applicators had been returned
empty and were regarded as ‘used’. Each month, women returned an average of 5.9
(median: 6.0, interquartile range (IQR): 4 – 7) used applicators.
Self-reported adherence
According to self-reports, 459 of 889 women reported using both the before and after gel
dose every month for the last sex act. Of the 459 women, 209 women missed at least 1
monthly visit. The remaining 250 women did not miss any visits during the study and they
were regarded as high adherers as per the self-reported adherence measures (Table 3).
Average gel adherence based on the women's self-report of their last sex acts was 82.0%
(IQR: 76.5 – 100). Most self-reported last sex acts (96.6%) involved correct gel use, with
1.6% reporting gel use after sex only and 1.8% reporting gel use before sex only.
The majority of last sex acts (69.2%) had gel use within 5 hours before sex and 3 hours after
sex (Figure 2). Women who inserted gel within two hours before the sex act were more
likely to insert gel within 2 hours after sex [OR 1.73 (95% CI 1.56 - 1.93), p<0.0001]
compared to those inserting gel more than two hours before the sex act.
Self-reported data collected for the last sex act indicated that women used both a condom
and gel for 79.6% of sex acts, used a condom only for 2.3% of sex acts, and used gel only
for 17.3% of last sex acts. No differences were noted in self-reported condom use between
the study arms, but was higher at the urban than the rural site (90.9% vs 77.7%, p<0.001).
Applicator-based adherence (primary adherence measure)
Data on the applicator-based adherence has been previously reported. In brief, a mean of
72.2% (IQR: 50 - 100) of reported sex acts were estimated to have had two gel doses (8).
Gel adherence and effectiveness
All three adherence measures demonstrate that women who were high adherers had the
highest tenofovir gel effectiveness (Table 3). High gel adherence based on returned used
applicators, self-reported adherence and applicator-based adherence produced anti-HIV
effectiveness estimates of 54%, 64% and 55% respectively. Eighteen women were classified
as high adherers, irrespective of the adherence measure used. Of these 0/10 in the tenofovir
gel arm and 4/8 in the placebo gel arm acquired HIV (p=0.02). Tenofovir gel reduced HIV
infection by an estimated 79% in the group of women who had a high median applicator use
(>9) and a high primary adherence measure (>80%), with an HIV incidence rate of 3.9 per
100 person-years (95% CI 0.5 – 14.2) in the tenofovir gel arm and 19.0 per 100 person-years
(95%CI 8.2 – 37.4) in the placebo gel arm. A total of 64 women were classified as low
adherers, irrespective of the adherence measure used. Of these 2/26 in the tenofovir gel arm
and 4/38 in the placebo gel arm acquired HIV, with respective HIV incidence rates of 6.2
per 100 person-years (95% CI: 0.7-22.2) and 8.3 per 100 person-years (95% CI: 2.3-21.3)
(p=0.73).
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Adherence is a major challenge in microbicide trials and well-developed programs to
enhance adherence are critical. Adherence ranging from 72.2% to 82.0%, depending on the
measure used, was achieved in the CAPRISA 004 study using an IMB-based adherence
support program. Women with high adherence had the highest levels of protection, with
effectiveness against HIV ranging from 54% to 64%, depending on which of the three
measurements of adherence was used.
Based on self-reports, high levels of adherence were achieved during the last sex act before
each monthly clinic visits. The discrepancy between the self-reported adherence of 82.0% in
the last sex act and the mean applicator-based adherence of 72.2% in the last month may
reflect a “white coat” effect of higher adherence in the last sex act prior to a scheduled study
visit compared to the rest of the month. Given that the CAPRISA 004 ASP, through the
individualized sessions, repeatedly emphasized the importance of adherence, data obtained
from self-report may also be subject to social desirability bias (29). Self-reported adherence
has often been shown to be an overestimate of true adherence when compared to a more
objective marker of adherence such as plasma drug levels. In the FEM-PrEP trial (10) self-
reported adherence was 95%, however only 26% of women had detectable drug levels at the
beginning of the infection window. Similarly in the VOICE trial (11) the overall adherence
by self-report was 90%, however drug levels were detected in only 25-30 % of participant
samples depending on the study arm. Another objective marker of adherence is the
applicator dye test used in the Carraguard trial (5, 30), where self-reported adherence was
96% compared to 41% based on the dye stain. Self-reported adherence also has other
limitations, including inadequate recall, misunderstanding of questions and recall for the last
sex act may not be representative of the sexual behavior throughout the month (29).
While returned applicators are a more direct, objective measure of gel use in the previous
month, this method is still dependent on participant behavior (31) and does not account for
sexual frequency, possible gel dumping or that participants could forget to return
applicators. To overcome some of these limitations, data from self-report were combined
with the objective applicator count data to obtain a more accurate applicator-based
adherence measurement (primary adherence measure) for the preceding 30 days. While this
combined measure may have its own limitations, effectiveness in preventing HIV infection
was consistently higher among women considered to be high adherers.
Achieving good adherence requires more than access to accurate information; it is an
interplay of several factors including contextualizing of information, motivation and
behavior change skills (24). Adherence may be influenced by multiple factors, such as
unpredictable patterns of coital activity and risk-taking behavior (9), disclosure of product
use (32) and fatigue with clinical trial requirements combined with using a product of
uncertain benefit (33). The motivational interviewing approach of the CAPRISA 004 ASP
was a novel application for the microbicide field to identify, address and support a woman's
decision making and allow her to anticipate situations that could lead to non-adherence.
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There were several challenges in implementing the CAPRISA 004 ASP activities. Women
recruited for the CAPRISA 004 trial came from diverse settings, including local family
planning clinics and sexually transmitted infection clinics, which required nurses to be
flexible and they had to tailor their interviewing techniques for each population accordingly.
For example, the ability of women with multiple concurrent partners to negotiate safe sex
may vary between casual and stable partners. In addition, ongoing staff motivation was
identified as a challenge, despite the trial staff being well-trained. This problem was
compounded as the size of the trial cohort and diversity of the women's needs grew.
Ongoing monitoring of the ASP was essential to its continual improvement and refinement.
Further, it ensured quality, reinforced key messages and enhanced the women's acceptance
of the ASP. The interviews were conducted in a supportive environment and ultimately led
to customized goals to help each woman overcome her particular challenges.
Although the ASP was derived from a generalized theoretical framework with broad
applicability, it was customized for CAPRISA 004 and would need to be modified and
tailored to suit other clinical trials and populations. Additionally, the feasibility of applying
an intensive behavioral intervention outside of a trial context is questionable. For example,
the monthly booster sessions would require high staffing levels and it is not known whether
women would be willing to attend monthly sessions for routine HIV prevention. On the
other hand, adherence to a known effective product may offer its own incentives and less
intensive activities may prove as effective under those conditions.
CONCLUSION
The success of any microbicide trial investigating a new drug rests largely on the
individual's willingness and ability to use the investigational product as instructed. Our
experiences with a structured, theory-based approach to enhancing gel use in a microbicide
trial was encouraging and laid a good foundation for future microbicide trials seeking to
attain high adherence. This method to enhance adherence may have utility for other HIV
prevention interventions that require sustained product use.
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Inter-relationships created between the adherence support team, adherence support program
coordinator, the clinical trial team and the study participants to monitor the delivery of the
Adherence Support Program in the CAPRISA 004 trial
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Time of application of the before and after doses of study gel based on data collected at the
last sex act before each month's study visit
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